Abbott Laboratories (NYSE: ABT) announced initial results from "Aviator," a phase 2b study of its interferon-free, investigational regimen for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE